Skip to content

Study · Not a test of the peptide alone · 2009

5 results

Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone.

McTavish H, Griffin RJ, Terai K, Dudek AZ

Translational research : the journal of laboratory and clinical medicine14 Mar 2009Cited by 6 (Europe PMC)

PMID19446281 (opens in a new tab)DOI10.1016/j.trsl.2009.02.005 (opens in a new tab)PepBankPUB-19446281
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome

    In mice with LNCaP xenografts, the IGF-methotrexate conjugate was more effective than free methotrexate, even at a 6.25-fold lower molar dosage.

    In plain wordsIn mice with prostate tumors, the conjugate worked better than free methotrexate even at a much lower molar dose.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseLNCaP xenograft tumor inhibition
    Study

    mousen: not reported in source

    LNCaP xenograft
    Comparator
    Free methotrexate
    Outcome group
    Tumor growth · Cancer

    Measurements

    molar dosage reduction versus free methotrexate
    6.25 fold
    LNCaP xenograft

    Source sentences

    Summary
    In vivo, however, in a mouse xenograft model using LNCaP cells, the IGF-methotrexate conjugate was more effective than free methotrexate even at a 6.25-fold lower molar dosage.
    1 context sentence
    Summary · context
    We report here the development of a novel covalent conjugate that contains the antifolate drug methotrexate coupled to an engineered variant of insulin-like growth factor-1 (IGF-1), long-R3-IGF-1, which was designed to target methotrexate to tumor cells that overexpress the membrane IGF-1 receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome

    In mice with MCF7 xenografts, the IGF-methotrexate conjugate inhibited tumors more effectively than free methotrexate, even at a 4-fold lower molar dosage.

    In plain wordsIn mice with breast tumors, the conjugate worked better than free methotrexate even at a 4-fold lower molar dose.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseMCF7 xenograft tumor inhibition
    Study

    mousen: not reported in source

    MCF7 xenograft
    Comparator
    Free methotrexate
    Outcome group
    Tumor growth · Cancer

    Measurements

    molar dosage reduction versus free methotrexate
    4 fold
    MCF7 xenograft

    Source sentences

    Summary
    Similarly, MCF7 xenografts were inhibited more effectively by the IGF-methotrexate conjugate than free methotrexate, even at a 4-fold lower molar dosage.
    2 context sentences
    Summary · context
    In vivo, however, in a mouse xenograft model using LNCaP cells, the IGF-methotrexate conjugate was more effective than free methotrexate even at a 6.25-fold lower molar dosage.
    Summary · context
    We report here the development of a novel covalent conjugate that contains the antifolate drug methotrexate coupled to an engineered variant of insulin-like growth factor-1 (IGF-1), long-R3-IGF-1, which was designed to target methotrexate to tumor cells that overexpress the membrane IGF-1 receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  3. 03LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Activity measurement

    In MCF7 breast cancer cells, the IGF-methotrexate conjugate bound with greater than 3.3-fold higher affinity than unconjugated long-R3-IGF-1.

    In plain wordsIn breast cancer cells in the lab, the conjugate bound its receptor more than 3.3 times more strongly than unconjugated long-R3-IGF-1.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseReceptor binding affinity of conjugate
    Study

    n: not reported in source

    MCF7 breast cancer cells
    Comparator
    Unconjugated long-R3-IGF-1
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    binding affinity versus unconjugated long-R3-IGF-1
    > 3.3 fold
    MCF7 cells

    Source sentences

    Summary
    The IGF-methotrexate conjugate bound to MCF7 breast cancer cells with greater than 3.3-fold higher affinity than unconjugated long-R3-IGF-1 in a competition binding assay against radiolabeled wild-type IGF-1.
    1 context sentence
    Summary · context
    We report here the development of a novel covalent conjugate that contains the antifolate drug methotrexate coupled to an engineered variant of insulin-like growth factor-1 (IGF-1), long-R3-IGF-1, which was designed to target methotrexate to tumor cells that overexpress the membrane IGF-1 receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  4. 04LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Efficacy outcome

    In LNCaP cells, the IGF-methotrexate conjugate inhibited growth in vitro but required slightly higher concentrations than free methotrexate.

    In plain wordsIn prostate cancer cells in the lab, the conjugate needed slightly higher doses than free methotrexate to slow growth.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseIn vitro growth inhibition of LNCaP cells
    Study

    humann: not reported in source

    LNCaP prostate cancer cell line
    Comparator
    Free methotrexate
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Compared with free methotrexate, the IGF-methotrexate conjugate required slightly higher concentrations to inhibit the in vitro growth of the human prostate cancer cell line LNCaP.
    1 context sentence
    Summary · context
    We report here the development of a novel covalent conjugate that contains the antifolate drug methotrexate coupled to an engineered variant of insulin-like growth factor-1 (IGF-1), long-R3-IGF-1, which was designed to target methotrexate to tumor cells that overexpress the membrane IGF-1 receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  5. 05LabNot a test of IGF-1 LR3 aloneIn vitro (cell-free)Other

    The IGF-methotrexate conjugate contained at least 4 methotrexate molecules per long-R3-IGF-1 protein.

    In plain wordsIn lab tests, each long-R3-IGF-1 protein in the conjugate carried at least 4 methotrexate molecules.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableMethotrexate molecules per IGF-1 protein in the conjugate
    Study

    n: not reported in source

    IGF-methotrexate conjugate
    Outcome group
    Peptide structure and chemistry · Pharmacology

    Measurements

    methotrexate per IGF-1 protein
    ≥ 4 molecules
    IGF-methotrexate conjugate

    Source sentences

    Summary
    The IGF-methotrexate conjugate was found to contain at least 4 methotrexate molecules per IGF-1 protein.
    1 context sentence
    Summary · context
    We report here the development of a novel covalent conjugate that contains the antifolate drug methotrexate coupled to an engineered variant of insulin-like growth factor-1 (IGF-1), long-R3-IGF-1, which was designed to target methotrexate to tumor cells that overexpress the membrane IGF-1 receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.